Physician profile
Su Bin Kim
NPI 1679826416
$2,956.97
in general payments reported to CMS, 2019-2025
23 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $60.58 · 2021: $26.61 · 2022: $1,540 · 2023: $401 · 2024: $57.68 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $706.58 | 2019-2025 | |
| Boston Scientific Corporation | $348.47 | 2019 | |
| Ardelyx, INC. | $345.18 | 2022-2025 | Ibsrela |
| Laborie Medical Technologies Corp. | $255.82 | 2022-2024 | |
| Janssen Biotech, INC. | $181.56 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Gilead Sciences, INC. | $161.02 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $147.59 | 2022-2023 | Gattex, Entyvio |
| Celgene Corporation | $127.00 | 2020-2022 | |
| Qol Medical, LLC | $122.26 | 2019-2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $91.50 | 2022-2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.72 | 2022-2023 | Xifaxan, Plenvu, Uceris |
| Genzyme Corporation | $64.00 | 2022-2023 | |
| Madrigal Pharmaceuticals | $58.68 | 2025 | Rezdiffra |
| Pfizer INC. | $39.31 | 2022-2023 | |
| Redhill Biopharma INC. | $38.23 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $36.37 | 2022 | |
| Vivus LLC | $34.55 | 2022-2023 | Qsymia |
| Regeneron Healthcare Solutions, INC. | $29.50 | 2022 | |
| Zimmer Biomet Holdings, INC. | $26.61 | 2021 | |
| Amgen INC. | $23.18 | 2023 | Amjevita |
| Shire North American Group INC | $19.83 | 2019 | |
| Pharmacosmos Therapeutics INC. | $12.46 | 2022 | |
| Organon LLC | $9.55 | 2023 | Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Su Bin Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.